Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Aggen

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Blood|May 16, 2013
Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selectionThomas M Schmitt, David H Aggen, Ingunn M Stromnes, et al.
Cancer Immunology, Immunotherapy : CII|August 2, 2014
A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor controlJennifer D Stone, Daniel T Harris, Carolina M Soto, et al.
Molecular Immunology|October 31, 2008
Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragmentsSarah A Richman, David H Aggen, Michelle L Dossett, et al.
The Prostate|January 4, 2020
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapyJessica E Hawley, Samuel Pan, William D Figg, et al.
European Urology|November 7, 2022
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy CombinationsKelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, et al.
Seminars in Oncology|November 24, 2019
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamideHarshraj Leuva, Keith Sigel, Mengxi Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate CancerMatthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional AnalysesDavid H Aggen, Casey R Ager, Aleksandar Z Obradovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial CarcinomaDavid H Aggen, Meredith McKean, Jean H Hoffman-Censits, et al.
Cell|May 21, 2021
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophagesAleksandar Obradovic, Nivedita Chowdhury, Scott M Haake, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Blood|May 16, 2013
Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selectionThomas M Schmitt, David H Aggen, Ingunn M Stromnes, et al.
Cancer Immunology, Immunotherapy : CII|August 2, 2014
A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor controlJennifer D Stone, Daniel T Harris, Carolina M Soto, et al.
Molecular Immunology|October 31, 2008
Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragmentsSarah A Richman, David H Aggen, Michelle L Dossett, et al.
The Prostate|January 4, 2020
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapyJessica E Hawley, Samuel Pan, William D Figg, et al.
European Urology|November 7, 2022
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy CombinationsKelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, et al.
Seminars in Oncology|November 24, 2019
A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamideHarshraj Leuva, Keith Sigel, Mengxi Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate CancerMatthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2020
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional AnalysesDavid H Aggen, Casey R Ager, Aleksandar Z Obradovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial CarcinomaDavid H Aggen, Meredith McKean, Jean H Hoffman-Censits, et al.
Cell|May 21, 2021
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophagesAleksandar Obradovic, Nivedita Chowdhury, Scott M Haake, et al.
Pageof 3